Trader consensus on Polymarket assigns an 81% implied probability to "No IPO before June 2026" for Encore Medical Inc., reflecting persistent delays in the IPO process despite an S-1 filing in September 2025 and multiple slipped pricing dates—from an initial April 22 target to the current week-of-May-18 expectation on NYSE American. The microcap medtech firm's fundamentals, including $2.1 million trailing-twelve-month revenue (up 48% year-over-year) but ongoing $1.5 million net losses, fixed $5/share pricing for a $15 million raise, and pre-FDA pivotal trial status for its PFO closure device amid competition from Abbott and Boston Scientific, fuel skepticism on timely execution. Secondary outcomes cluster around $45–55 million market cap at debut, with trader capital pricing low odds for completion by May 31 absent fresh SEC clearance or roadshow updates.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วNo IPO before June 2026 81%
55M+ 7.8%
45M–50M 7%
<45M 2.8%
$24,003 ปริมาณ
$24,003 ปริมาณ
Apr 22, 2026
<45M
3%
45M–50M
7%
50M–55M
8%
55M+
8%
No IPO before June 2026
81%
No IPO before June 2026 81%
55M+ 7.8%
45M–50M 7%
<45M 2.8%
$24,003 ปริมาณ
$24,003 ปริมาณ
Apr 22, 2026
<45M
$7,323 ปริมาณ
3%
45M–50M
$2,625 ปริมาณ
7%
50M–55M
$1,759 ปริมาณ
8%
55M+
$3,121 ปริมาณ
8%
No IPO before June 2026
$9,175 ปริมาณ
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket assigns an 81% implied probability to "No IPO before June 2026" for Encore Medical Inc., reflecting persistent delays in the IPO process despite an S-1 filing in September 2025 and multiple slipped pricing dates—from an initial April 22 target to the current week-of-May-18 expectation on NYSE American. The microcap medtech firm's fundamentals, including $2.1 million trailing-twelve-month revenue (up 48% year-over-year) but ongoing $1.5 million net losses, fixed $5/share pricing for a $15 million raise, and pre-FDA pivotal trial status for its PFO closure device amid competition from Abbott and Boston Scientific, fuel skepticism on timely execution. Secondary outcomes cluster around $45–55 million market cap at debut, with trader capital pricing low odds for completion by May 31 absent fresh SEC clearance or roadshow updates.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Apr 3, 2026, 7:59 PM ET
ปริมาณการซื้อขาย
$24,003วันสิ้นสุด
Apr 22, 2026ตลาดเปิดเมื่อ
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket assigns an 81% implied probability to "No IPO before June 2026" for Encore Medical Inc., reflecting persistent delays in the IPO process despite an S-1 filing in September 2025 and multiple slipped pricing dates—from an initial April 22 target to the current week-of-May-18 expectation on NYSE American. The microcap medtech firm's fundamentals, including $2.1 million trailing-twelve-month revenue (up 48% year-over-year) but ongoing $1.5 million net losses, fixed $5/share pricing for a $15 million raise, and pre-FDA pivotal trial status for its PFO closure device amid competition from Abbott and Boston Scientific, fuel skepticism on timely execution. Secondary outcomes cluster around $45–55 million market cap at debut, with trader capital pricing low odds for completion by May 31 absent fresh SEC clearance or roadshow updates.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$24,003วันสิ้นสุด
Apr 22, 2026ตลาดเปิดเมื่อ
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader consensus on Polymarket assigns an 81% implied probability to "No IPO before June 2026" for Encore Medical Inc., reflecting persistent delays in the IPO process despite an S-1 filing in September 2025 and multiple slipped pricing dates—from an initial April 22 target to the current week-of-May-18 expectation on NYSE American. The microcap medtech firm's fundamentals, including $2.1 million trailing-twelve-month revenue (up 48% year-over-year) but ongoing $1.5 million net losses, fixed $5/share pricing for a $15 million raise, and pre-FDA pivotal trial status for its PFO closure device amid competition from Abbott and Boston Scientific, fuel skepticism on timely execution. Secondary outcomes cluster around $45–55 million market cap at debut, with trader capital pricing low odds for completion by May 31 absent fresh SEC clearance or roadshow updates.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย